Researchers from Generate Biomedicines Inc. have detailed the discovery and preclinical characterization of GB-0669, a spike S2-targeted monoclonal antibody (MAb) being developed for the prophylaxis of SARS-CoV-2 infection. Machine learning models were used to identify MAbs targeting the conserved S2 stem helix and RBD class IV region of spike.

Salipro Biotech AB and Icosagen AS have entered into a multitarget antibody research agreement for the discovery and characterization of monoclonal antibodies against several challenging membrane proteins.

The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response, has awarded Vir Biotechnology Inc. approximately $50 million in new funding to advance the development of novel monoclonal antibody (MAb) candidates and delivery solutions to widen the applicability of MAbs in COVID-19 and in pandemic preparedness and response.

The FDA has cleared an IND application for ADEL-Y01, being jointly developed by Oscotec Inc. and Adel Inc., for the treatment of Alzheimer’s disease. A phase Ia/b study will include healthy volunteers, and participants with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease.

Biomarin Pharmaceutical Inc. has reported progress across its research and development portfolio, including early-stage product candidates.

Antoxa Corp. and Swiftpharma BV have signed an exclusive collaboration agreement to support the development and commercialization of a plant-made monoclonal antibody against ricin exposure.

Most of the West African population is at risk of infection with Lassa virus (LASV), which leads to Lassa fever that causes thousands of deaths every...